Taken all, BACH1 mediates activation of aerobic glycolysis pathways and the metastatic process of lung cancer cells, as inhibition of BACH1 using either shRNA, sgRNA, or hemin treatment decreases migration and metastasis of cancer cells through aerobic glycolysis reduction. Here, BACH1 is linked to lung carcinoma.